DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for polycystic kidney disease 7 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePolycystic kidney disease 7 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for polycystic kidney disease 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In autosomal dominant polycystic kidney disease (ADPKD), which has a population prevalence of about 1 in 1,000 individuals, mutations in PKD1 (responsible for roughly 85% of cases) or PKD2 lead to multiple fluid-filled cysts that enlarge over time and destroy kidney structure and function, causing end-stage kidney disease usually between the 4th and 7th decade of life. The polycystin 1 protein, encoded by PKD1, is a large receptor-like protein that interacts with multiple signalling pathways including the G-protein coupled receptor, cAMP, Wnt, mTOR, MAPK/ERK, AP1 and JAK-STAT pathways, and its cleaved C-terminal domain can translocate to the nucleus to influence gene transcription.
Studies of simple and syndromic forms of polycystic kidney disease have shown that the defective proteins localise to the primary cilia and basal body, and that the pleiotropic phenotypes are often associated with defective ciliogenesis. The polycystins are involved in ciliary mechanosensation and in cellular changes in intracellular calcium and cAMP, which have provided clues for therapeutic approaches that proved highly effective in preclinical trials. A 2007 review noted that many animal models for testing these therapies were available, and that some early-phase clinical trials were already being implemented.
By 2012, the question was raised whether suppressing cyst growth is sufficient to preserve renal function. The abstracts do not report any concrete survival or response rate numbers from clinical trials in patients. No drug is named in these abstracts. What remains missing is evidence from completed, adequately powered clinical trials that show whether targeting the downstream cellular changes (such as cAMP or mTOR pathways) actually slows the loss of kidney function in patients, and whether any such effect is large enough to delay dialysis or transplantation. The necessary patient stratification by PKD1 versus PKD2 mutation, and by rate of kidney growth, has not yet been validated in prospective trials with hard renal endpoints.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Internal Medicine · 2007 · 126 citations · open access
AbstractAn increased understanding of the genetic, molecular and cellular mechanisms responsible for the development of polycystic kidney disease has laid out the foundation for the development of rational therapies. Many animal models where these therapies can be tested are currently available. This review summarizes the rationale for these treatments, the results of preclinical trials and the prospects for clinical trials, some already in early phases of implementation.
Current Opinion in Nephrology & Hypertension · 2006 · 42 citations
Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy
AbstractPURPOSE OF REVIEW: Polycystic kidney diseases are a group of inherited disorders that result in tubular dilatation and/or the development of fluid-filled cysts in the kidney. Identification and analysis of the primary defective protein in many of these diseases are providing insights into a common pathogenesis to polycystic kidney disease. This review explores this pathogenesis and determines the role that this knowledge is playing in the development of potential therapies. RECENT FINDINGS: Study of simple and syndromic forms of polycystic kidney disease has revealed that the defective proteins are localized to the primary cilia/basal body and that the pleiotropic phenotypes are often associated with defective ciliogenesis. Data indicating that the polycystins are involved in ciliary mechanosensation, and cellular changes in intracellular Ca and cAMP, have provided clues for possible therapeutic approaches that have proved highly effective in pre-clinical trials. SUMMARY: Polycystic kidney diseases are associated with defects to proteins involved in developing functional, sensory cilia in the kidney. While the primary defects in these disorders cannot be corrected at present, downsteam cellular changes can be targeted. Potential therapeutic agents are now being tested in patients, moving polycystic kidney disease research into a new and exciting phase.
Is suppression of cyst growth in PKD enough to preserve renal function?
AbstractThe autosomal dominant form of polycystic kidney disease (ADPKD) is one of the most frequent monogenic disorders and the most frequent among inherited kidney disorders. In fact it has a prevalence in the population of about 1/1,000 individuals, therefore it does not even satisfy the definition for rare diseases. It is mainly characterized by the formation of multiple cysts filled with fluid that over time develop in number and size leading to the distraction of the structure and function of the kidneys and eventually leading to chronic kidney disease/end stage kidney disease (CKD/ESKD), usually between the 4th and 7th decade of life. There are two known forms of the autosomal dominant type of polycystic kidney disease, type 1 and type 2, caused by mutations in the PKD1 and PKD2 genes, located on chromosomes 16 and 4 respectively. The polycystin 1 protein, encoded by PKD1 and mutated in ~85% of patients, is a huge protein of 4,302 amino acids with multiple transmembrane domains, 200 residues intracytoplasmic part and a huge extracellular part with multiple Ig-like PKD repeats, which probably acts as a receptor to an unknown ligand. Polycystin 1 has been shown to interact with and participate in multiple signal transduction pathways, including the G-protein coupled receptor, cAMP pathway, Wnt, mTOR, MAPK/ERK, AP1 and JAK-STAT pathway, while its intracytoplasmic C-terminal domain has been shown to be cleaved and translocated to the nucleus where it plays a role in gene transcription, in concert with P100 and STAT6.(1.)
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
